课题基金 / 基金详情

Repurposing Histamine Receptor 1 (HR1) blockers for host directed therapy of tuberculosis

重新利用组胺受体 1 (HR1) 阻滞剂用于结核病的宿主定向治疗

批准号：

491202

负责人：

Sahile Henok A

金额：

$19.67万

依托单位：

University of British Columbia

依托单位国家：

加拿大

项目类别：

Fellowship Programs

财政年份：

2023

资助国家：

加拿大

项目状态：

未结题

起止时间：

2023-05-01 至 2026-05-01

来源：

https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=491202&lang=en

关键词：

Antihistamine Drugs Drug Discovery Drug Repurposing Host Directed Therapy Medicinal Chemistry Tuberculosis

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

The cause of tuberculosis (TB) was known before 100 years and since then several drugs and diagnostic tools have been developed. Despite all efforts, until the recent COVID-19 pandemic, TB was the deadliest infectious disease killing every year about 1.6

期刊论文(0)

专著(0)

科研奖励(0)

会议论文